- Home
- ZVSA vs NCNA Comparison
ZVSA vs NCNA Comparison
Compare ZVSA & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZVSA
- NCNA
- Stock Information
- Founded
- ZVSA 2014
- NCNA 1997
- Country
- ZVSA United States
- NCNA United Kingdom
- Employees
- ZVSA N/A
- NCNA N/A
- Industry
- ZVSA Biotechnology: Pharmaceutical Preparations
- NCNA Biotechnology: Pharmaceutical Preparations
- Sector
- ZVSA Health Care
- NCNA Health Care
- Exchange
- ZVSA Nasdaq
- NCNA Nasdaq
- Market Cap
- ZVSA 3.5M
- NCNA 3.4M
- IPO Year
- ZVSA N/A
- NCNA 2017
- Fundamental
- Price
- ZVSA $0.59
- NCNA $0.97
- Analyst Decision
- ZVSA Strong Buy
- NCNA Buy
- Analyst Count
- ZVSA 1
- NCNA 2
- Target Price
- ZVSA $240.00
- NCNA $25.00
- AVG Volume (30 Days)
- ZVSA 125.6K
- NCNA 118.8K
- Earning Date
- ZVSA 05-14-2025
- NCNA 05-15-2025
- Dividend Yield
- ZVSA N/A
- NCNA N/A
- EPS Growth
- ZVSA N/A
- NCNA N/A
- EPS
- ZVSA N/A
- NCNA N/A
- Revenue
- ZVSA N/A
- NCNA N/A
- Revenue This Year
- ZVSA N/A
- NCNA N/A
- Revenue Next Year
- ZVSA N/A
- NCNA N/A
- P/E Ratio
- ZVSA N/A
- NCNA N/A
- Revenue Growth
- ZVSA N/A
- NCNA N/A
- 52 Week Low
- ZVSA $0.58
- NCNA $0.69
- 52 Week High
- ZVSA $8.05
- NCNA $10.79
- Technical
- Relative Strength Index (RSI)
- ZVSA 27.23
- NCNA 48.38
- Support Level
- ZVSA $0.69
- NCNA $0.81
- Resistance Level
- ZVSA $0.65
- NCNA $1.34
- Average True Range (ATR)
- ZVSA 0.06
- NCNA 0.14
- MACD
- ZVSA -0.00
- NCNA 0.02
- Stochastic Oscillator
- ZVSA 3.04
- NCNA 29.20
About ZVSA ZyVersa Therapeutics Inc.
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States.